Literature DB >> 26366428

Ketamine - A Multifaceted Drug.

Lingzhong Meng1, Jian Li2, Yi Lu3, Dajin Sun4, Yuan-Xiang Tao5, Renyu Liu6, Jin Jun Luo7.   

Abstract

There is a petition for tight control of ketamine from the Chinese government to classify ketamine as a Schedule I drug, which is defined as a drug with no currently accepted medical use but a high potential for abuse. However, ketamine has unique properties that can benefit different patient populations. Scholars from the Translational Perioperative and Pain Medicine and the International Chinese Academy of Anesthesiology WeChat groups had an interactive discussion on ketamine, including its current medical applications, future research priorities, and benefits versus risks. The discussion is summarized in this manuscript with some minor edits.

Entities:  

Year:  2015        PMID: 26366428      PMCID: PMC4563343     

Source DB:  PubMed          Journal:  Transl Perioper Pain Med


  9 in total

1.  Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.

Authors:  J H Krystal; I L Petrakis; E Webb; N L Cooney; L P Karper; S Namanworth; P Stetson; L A Trevisan; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1998-04

2.  General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metastases by suppression of natural killer cell activity.

Authors:  S Katzav; J Shapiro; S Segal; M Feldman
Journal:  Isr J Med Sci       Date:  1986-05

Review 3.  Opioid therapy and immunosuppression: a review.

Authors:  Ricardo Vallejo; Oscar de Leon-Casasola; Ramsun Benyamin
Journal:  Am J Ther       Date:  2004 Sep-Oct       Impact factor: 2.688

4.  Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors.

Authors:  J Shapiro; J Jersky; S Katzav; M Feldman; S Segal
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

5.  Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures.

Authors:  Rivka Melamed; Shahar Bar-Yosef; Guy Shakhar; Keren Shakhar; Shamgar Ben-Eliyahu
Journal:  Anesth Analg       Date:  2003-11       Impact factor: 5.108

Review 6.  Opioid-induced immunosuppression.

Authors:  Paola Sacerdote
Journal:  Curr Opin Support Palliat Care       Date:  2008-03       Impact factor: 2.302

7.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

Review 8.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.

Authors:  A McGirr; M T Berlim; D J Bond; M P Fleck; L N Yatham; R W Lam
Journal:  Psychol Med       Date:  2014-07-10       Impact factor: 7.723

9.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Authors:  James W Murrough; Dan V Iosifescu; Lee C Chang; Rayan K Al Jurdi; Charles E Green; Andrew M Perez; Syed Iqbal; Sarah Pillemer; Alexandra Foulkes; Asim Shah; Dennis S Charney; Sanjay J Mathew
Journal:  Am J Psychiatry       Date:  2013-10       Impact factor: 18.112

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.